SI2229185T1 - Sočasno dajanje sredstva, vezanega na internalizacijski peptid tat, s protivnetnim sredstvom - Google Patents

Sočasno dajanje sredstva, vezanega na internalizacijski peptid tat, s protivnetnim sredstvom

Info

Publication number
SI2229185T1
SI2229185T1 SI200831555T SI200831555T SI2229185T1 SI 2229185 T1 SI2229185 T1 SI 2229185T1 SI 200831555 T SI200831555 T SI 200831555T SI 200831555 T SI200831555 T SI 200831555T SI 2229185 T1 SI2229185 T1 SI 2229185T1
Authority
SI
Slovenia
Prior art keywords
agent
administration
internalization peptide
linked
tat internalization
Prior art date
Application number
SI200831555T
Other languages
English (en)
Slovenian (sl)
Inventor
Michael Tymianski
Jonathan David Garman
Original Assignee
Nono Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc. filed Critical Nono Inc.
Publication of SI2229185T1 publication Critical patent/SI2229185T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200831555T 2007-12-05 2008-12-02 Sočasno dajanje sredstva, vezanega na internalizacijski peptid tat, s protivnetnim sredstvom SI2229185T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99267807P 2007-12-05 2007-12-05
EP08859906.3A EP2229185B8 (en) 2007-12-05 2008-12-02 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory agent
PCT/US2008/085280 WO2009076105A2 (en) 2007-12-05 2008-12-02 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Publications (1)

Publication Number Publication Date
SI2229185T1 true SI2229185T1 (sl) 2016-02-29

Family

ID=40756064

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831555T SI2229185T1 (sl) 2007-12-05 2008-12-02 Sočasno dajanje sredstva, vezanega na internalizacijski peptid tat, s protivnetnim sredstvom

Country Status (14)

Country Link
US (1) US8080518B2 (enExample)
EP (1) EP2229185B8 (enExample)
JP (1) JP5520230B2 (enExample)
CN (1) CN101970011B (enExample)
AU (1) AU2008335490B2 (enExample)
BR (1) BRPI0820912B1 (enExample)
DK (1) DK2229185T3 (enExample)
ES (1) ES2555524T3 (enExample)
HR (1) HRP20151312T1 (enExample)
HU (1) HUE027216T2 (enExample)
PL (1) PL2229185T3 (enExample)
PT (1) PT2229185E (enExample)
SI (1) SI2229185T1 (enExample)
WO (1) WO2009076105A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
ES2804424T3 (es) * 2006-07-11 2021-02-08 Nono Inc Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
JP6005357B2 (ja) * 2008-05-16 2016-10-12 ノノ インコーポレイテッド てんかんの治療
AU2009288088B2 (en) * 2008-09-03 2014-12-04 Nono Inc. Agents and methods for treatment of pain
BRPI1010718A2 (pt) 2009-06-10 2016-03-15 Nono Inc sistemas modelo e regimes de tratamento para tratar doença neurológica.
AU2010259986B2 (en) 2009-06-10 2015-04-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2011038397A2 (en) * 2009-09-28 2011-03-31 Duke University Peptide adjuvants, vaccines, and methods of use
JP2013527834A (ja) * 2010-03-29 2013-07-04 マサチューセッツ インスティテュート オブ テクノロジー 抗炎症因子
EP2580233B1 (en) * 2010-06-10 2016-08-10 Indiana University Research And Technology Corporation Materials and method for suppressing inflammatory and neuropathic pain
EP2616094B1 (en) * 2010-08-12 2017-11-08 NoNO Inc. Treatment of penetrative injury to the brain
KR102046830B1 (ko) * 2011-05-13 2019-11-20 코벤하븐스 유니버시테트 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제
KR102022116B1 (ko) 2011-06-24 2019-09-18 노노 인코포레이티드 허혈에 대한 psd-95 억제제와의 조합 요법
US9730921B2 (en) 2012-03-27 2017-08-15 Duke University Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
HUE043820T2 (hu) * 2012-11-28 2019-09-30 Nono Inc Liofilizált TAT-NR2B9c készítmény
WO2014150350A1 (en) * 2013-03-15 2014-09-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the linear ubiquitin chain assembly complex (lubac) and related methods
US20140349944A1 (en) * 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
ES2600488T3 (es) 2014-05-23 2017-02-09 Ares Trading S.A. Composición farmacéutica líquida
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
WO2016049280A1 (en) * 2014-09-24 2016-03-31 Memorial Sloan Kettering Cancer Center mTORC1 MODULATION
WO2019061395A1 (zh) * 2017-09-30 2019-04-04 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1159418A2 (en) * 1998-12-11 2001-12-05 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
DE60026313D1 (de) * 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
MXPA02001857A (es) * 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US6864355B1 (en) * 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20020032154A1 (en) * 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
AU2002356511A1 (en) * 2001-07-30 2003-04-01 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
US20060276455A1 (en) * 2003-02-13 2006-12-07 Lindsberg Perttu J Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
EP2801366A3 (en) * 2004-09-02 2015-04-29 Cognosci, Inc. Improved apo E analogs and methods for their use
US7151084B2 (en) * 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
WO2009006611A1 (en) * 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
EP2178549B1 (en) * 2007-07-26 2016-09-14 Revance Therapeutics, Inc. Antimicrobial peptide and compositions thereof
ES2328776B1 (es) * 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
AU2010259986B2 (en) 2009-06-10 2015-04-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Also Published As

Publication number Publication date
CN101970011A (zh) 2011-02-09
AU2008335490A1 (en) 2009-06-18
JP2011506328A (ja) 2011-03-03
BRPI0820912A2 (pt) 2018-07-17
AU2008335490B2 (en) 2013-08-22
WO2009076105A3 (en) 2010-01-07
CN101970011B (zh) 2013-04-24
JP5520230B2 (ja) 2014-06-11
DK2229185T3 (en) 2016-01-11
EP2229185A2 (en) 2010-09-22
EP2229185B8 (en) 2016-12-21
ES2555524T3 (es) 2016-01-04
BRPI0820912B1 (pt) 2022-05-24
PL2229185T3 (pl) 2016-03-31
EP2229185B1 (en) 2015-10-07
WO2009076105A2 (en) 2009-06-18
US20090176713A1 (en) 2009-07-09
HRP20151312T1 (hr) 2016-03-11
EP2229185A4 (en) 2011-11-23
PT2229185E (pt) 2016-01-26
US8080518B2 (en) 2011-12-20
HUE027216T2 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
SI2229185T1 (sl) Sočasno dajanje sredstva, vezanega na internalizacijski peptid tat, s protivnetnim sredstvom
IL230542B (en) Anti-inflammatory factors
ZA201104497B (en) Peptide therapeutic conjugates and uses thereof
EP2403852B8 (en) 2-aminobenzimidazole-5-carboxamides as anti-inflammatory agents
IL233822A0 (en) New anti-inflammatory agents
IL209741A0 (en) Anti-inflammatory agents
EP2473161A4 (en) TOPICAL FORMULATIONS WITH A STEROID
EP2440231A4 (en) COMMON ADMINISTRATION OF A MEDIUM AND AN INFLAMMATORY AGENT COMPOSED WITH AN INTERNALIZATION PEPTIDE
SI2229940T1 (sl) Farmacevtski sestavek s protivnetnimi in antihistaminskimi lastnostmi
PL2344130T3 (pl) Kompozycje farmaceutyczne do miejscowego stosowania
EP2433631A4 (en) ANTI-INFLAMMATORY COMPOSITION CONTAINING MACROLACTIN A AND DERIVATIVE THEREOF AS ACTIVE INGREDIENTS
IL210820A0 (en) Topical anti-inflammatory compositions and uses thereof
IL216626A0 (en) Albumin-amyloid peptide conjugates and uses thereof
PT3417708T (pt) Administração de ibuprofeno intravenoso
EP2296687A4 (en) PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN DOPAMINE CONJUGATES
EP2151237A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF A NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTICONVULSIVE AGENT
EP2310022A4 (en) TOPIC MEDICINE
ZA201200092B (en) Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
EP2510000A4 (en) Anti-inflammatory antibodies and applications thereof
ZA201208210B (en) A combination composition comprising ibuprofen and paracetamal
AP2788A (en) Simalikalactone E and use thereof as a medicament
AP2012006560A0 (en) Anti-inflammatory agents
WO2011072138A9 (en) Therapeutic use of protein-polymer conjugates
AU2009904787A0 (en) Anti-inflammatory agents
GB0618363D0 (en) Improved use of anti-inflammatory glucocorticosteroids